A Randomized, Open-Label, Active-Controlled, Multicenter Study to Compare Efficacy and Safety of ABT-493/ABT-530 to Sofosbuvir Co-Administered With Daclatasvir in Adults With Chronic Hepatitis C Virus Genotype 3 Infection (ENDURANCE-3)

The purpose of this study was to compare the safety and efficacy of ABT-493/ABT-530 to the combination of sofosbuvir (SOF) and daclatasvir (DCV) in adults with genotype 3 (GT3) chronic hepatitis C virus (HCV) infection.

本研究旨在对比ABT-493/ABT-530与索磷布韦（sofosbuvir，SOF）联合达卡他韦（daclatasvir，DCV）在基因型3（GT3）慢性丙型肝炎病毒（HCV）感染成人患者中的安全性与有效性。